奥希替尼的合成工艺改进

以2-甲氧基-4-氟苯胺(2)为原料,用硝酸铵代替硝酸钾进行硝化反应得2-氟-4-甲氧基-5-硝基苯胺(3),进而与丙烯酰氯进行酰胺化反应得N-(2-氟-4-甲氧基-5-硝基)苯基-2-丙烯酰胺(4).4与N,N,N-三甲基乙二胺进行亲核取代反应时,加入阻聚剂对羟基苯甲醚,成功地降低了副反应Michael加成反应的发生...     

乐伐替尼的合成

以4-氨基-2-甲氧基苯甲酸甲酯为原料,与米氏酸、原甲酸三甲酯发生缩合得到4-[(2,2-二甲基-4,6-二氧代-1,3-二噁烷-5-亚甲基)氨基]-2-甲氧基苯甲酸甲酯(4),随后经环合、氯代、氨化反应生成4-氯-7-甲氧基喹啉-6-甲酰胺(7)。7与3-氯-4-氨基苯酚盐酸盐反应制得4-(4-氨基-3-氯苯氧基)-7-甲氧基喹啉-6-甲酰胺(8),最后与氯甲酸苯酯、环丙胺经一锅反应制得乐伐替尼。目标产物结构经核磁、质谱分析得到确证,总收率约34%(以4-氨基-2-甲氧基苯甲酸甲酯计)。改进后的工艺操作简单,降低了原料成本,且各步反应收率较高。     

抗肿瘤药物仑伐替尼合成研究进展

综述了仑伐替尼及其相关主要中间体的合成方法。首先对仑伐替尼逆合成分析,并着重讨论了喹啉环(原料1)以及终产物仑伐替尼的合成。原料1有四种合成方法,对这四种合成方法进行了详细对比与分析,指出第二种合成方法为最佳合成方法。总结了仑伐替尼最常用的两条合成路线并分析优缺点,第一条路线是汇聚式路线,反应时间短、能耗少、成本低、收率高,相比第二条路线更加适合工业化生产。     

吉非替尼的合成新工艺研究

以6-羟基-7-甲氧基喹唑啉-4-酮(1)为起始原料,在离子液体催化下与N-(3-氯丙基)吗啉(2)醚化,然后经氯代再与3-氯-4-氟苯胺进行亲核取代反应,得到目标产物吉非替尼,三步反应总收率为68.7%。通过改变反应物配比、离子液体用量和反应温度,得到了关键中间体3的优化制备工艺条件:n(1)∶n(2)=1.0∶1.2;离子液体四氟硼酸1-甲基-4-丁基咪唑鎓用量为原料1的质量的5%;95℃下反应5h。在此条件下,醚化收率约93.6%。该路线具有反应条件温和、分离简单、路线短和总收率较高的特点,为吉非替尼的工业化生产提供了实验依据。     

拉帕替尼新中间体的合成

通过使用市售的5-溴糠醛与2-甲磺酰基乙胺进行亲和加成得到席夫碱,该席夫碱通过还原氢化、氨基保护和与硼酸酯反应,得到一种拉帕替尼的新中间体5-((苄基(2-(甲基磺酰基)乙基)氨基)甲基)呋喃-2-基硼酸,四步反应总收率为66.32%。     

小分子蛋白酪氨酸激酶抑制剂的合成研究进展

蛋白酪氨酸激酶在肿瘤的形成和增殖中起着关键作用,以蛋白酪氨酸激酶作为肿瘤治疗靶点的研究受到极大关注.本文作者综述了近十年来不同结构的酪氨酸激酶抑制剂的合成以及抗肿瘤活性的研究进展,以期为酪氨酸激酶抑制剂的研究与开发提供参考.     

吉非替尼的合成工艺改进

以3-羟基-4-甲氧基苯甲醛为原料,先与N-(3-氯丙基)吗啉缩合,后依次经过醛基转化为氰基、硝化、还原、与3-氯-4-氟苯胺环合等反应合成了抗肿瘤药物吉非替尼,总收率约50%。其结构经1H NMR,MS和元素分析表征。     

靶向RET抑制剂塞尔帕替尼的合成进展

塞尔帕替尼是一种高选择性转染过程中重排(RET)受体酪氨酸激酶抑制剂,由Loxo Oncology公司研发于2020年5月在美国获批上市用于治疗RET融合阳性非小细胞肺癌、RET融合阳性甲状腺癌和RET突变甲状腺髓样癌。本文综述了目前报道的有关塞尔帕替尼的合成方法研究进展,并讨论了各方法的特点,以期对其工业化生产提供参考。     

拉帕替尼类似物的合成及抗肿瘤活性研究

以N'-(2-氰基-4-碘苯基)-N,N-二甲基甲脒为原料,经过Dimroth重排反应、Suzuki偶联、还原氨化3步反应合成了4种新型的拉帕替尼类似物。借助NMR、IR和HRMS对反应中间体和目标化合物进行结构表征,并采用MTT法在SW480、A549和A431人肿瘤细胞上进行了这些化合物抗肿瘤活性的初步体外评价。结果表明,以上4种化合物均具有明显的抑制肿瘤细胞生长作用,特别是化合物5a对所试肿瘤细胞均表现出良好的生长抑制活性(IC50:5.78~13.38μmol/L),与临床使用的抗肿瘤药物拉帕替尼的活性(IC50:4.80~14.90μmol/L)相当。     

拉罗替尼的合成工艺优化

以(R)-2-(2,5-二氟苯基)吡咯烷和5-氯-3-硝基吡唑并［1,5-a］嘧啶为起始原料,经胺化,还原,再与氯甲酸苯酯酰化,最后与(S)-3-羟基吡咯烷反应成盐后得到拉罗替尼,总收率为73.34%。其结构经¹H NMR、IR及ESI-MS 确证,并探讨了中间体和目标化合物合成工艺的影响因素。      

Synthesis of 6- and 7-propargyloxy derivatives of 4-(3-fluoroanilino)-quinazoline

The preparation of the novel isomeric 6- and 7-propargyloxy derivatives of 4-(3-fluoroanilino)-quinazoline was achieved using a six-step process. An alternate method to the 7-propargyloxy derivative and analogous 7-propargyloxy containing compounds is also described.     

嘧啶类酪氨酸激酶抑制剂

酪氨酸激酶在肿瘤的发生、发展过程中起着非常重要的作用,已成为肿瘤治疗的新靶点.嘧啶类化合物是蛋白酪氨酸酶抑制剂(PTKIs)中的一大类,这类化合物在临床前期研究中显示具有很好的抗肿瘤效应,一些已在临床上作为很有前景的抗癌药.本文按其结构类别介绍了近年来报道的嘧啶类酪氨酸激酶抑制剂.     

Gold nanoparticle-based electrochemical detection of protein phosphorylation

In this report, we demonstrate the application of Au nanoparticles in the electrochemical detection of protein phosphorylation. The method is based on the labeling of a specific phosphorylation event with Au nanoparticles, followed by electrochemical detection. The phosphorylation reaction is coupled with the biotinylation of the kinase substrate using a biotin-modified adenosine 5′-triphosphate [γ]-biotinyl-3,6,9-trioxaundecanediamine (ATP) as the co-substrate. When the phosphorylated and biotinylated kinase substrate is exposed to streptavidin-coated Au nanoparticles, the high affinity between the streptavidin and biotin resulted in the attachment of Au nanoparticles on the kinase substrate. The electrochemical response obtained from Au nanoparticles enables monitoring the activity of the kinase and its substrate, as well as the inhibition of small molecule inhibitors on protein phosphorylation. We determined the activity of Src non-receptor protein tyrosine kinase, p60^c-Src and protein kinase A in combination with their highly specific substrate peptides Raytide™ EL and Kemptide, respectively. The detection limits for Raytide™ EL and Kemptide were determined as 5 and 10 μM, (S/N = 3), and the detection limits for the kinase activity of p60^c-Src and protein kinase A (PKA) were determined as 5 and 10 U mL⁻¹, (S/N = 3), respectively. Tyrosine kinase reactions were also performed in the presence of a well-defined inhibitor, 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2), and its negative control molecule, 4-amino-7-phenylpyrazol[3,4-d] pyrimidine (PP3), which had no inhibition effect. Based on the dependency of Au nanoparticle signal on inhibitor concentration, IC₅₀ value, half-maximal inhibition of the inhibitors was estimated. IC₅₀ values of PP2, genistein and herbimycin A to p60^c-Src were detected as 5 nM, 25 μM and 900 nM, respectively. The inhibition of PKA activity on Kemptide using ellagic acid was monitored with an IC₅₀ of 3.5 μM. The performance of the biosensor was optimized including the kinase reaction, incubation with streptavidin-coated Au nanoparticles, and the small molecule inhibitors. Kinase peptide-modified electrochemical biosensors are promising candidates for cost-effective kinase activity and inhibitor screening assays.     

Binding energies of tyrosine kinase inhibitors: Error assessment of computational methods for imatinib and nilotinib binding

The binding energies of imatinib and nilotinib to tyrosine kinase have been determined by quantum mechanical (QM) computations, and compared with literature binding energy studies using molecular mechanics (MM). The potential errors in the computational methods include these critical factors:

• •Errors in X-ray structures such as structural distortions and steric clashes give unrealistically high van der Waals energies, and erroneous binding energies.
• •MM optimization gives a very different configuration to the QM optimization for nilotinib, whereas the imatinib ion gives similar configurations
• •Solvation energies are a major component of the overall binding energy. The QM based solvent model (PCM/SMD) gives different values from those used in the implicit PBSA solvent MM models. A major error in inhibitor—kinase binding lies in the non-polar solvation terms.
• •Solvent transfer free energies and the required empirical solvent accessible surface area factors for nilotinib and imatinib ion to give the transfer free energies have been reverse calculated. These values differ from those used in the MM PBSA studies.
• •An intertwined desolvation—conformational binding selectivity process is a balance of thermodynamic desolvation and intramolecular conformational kinetic control.
• •The configurational entropies (TΔS) are minor error sources.

     

Approach for the Design of Covalent Protein Kinase Inhibitors via Focused Deep Generative Modeling

Deep machine learning is expanding the conceptual framework and capacity of computational compound design, enabling new applications through generative modeling. We have explored the systematic design of covalent protein kinase inhibitors by learning from kinome-relevant chemical space, followed by focusing on an exemplary kinase of interest. Covalent inhibitors experience a renaissance in drug discovery, especially for targeting protein kinases. However, computational design of this class of inhibitors has thus far only been little investigated. To this end, we have devised a computational approach combining fragment-based design and deep generative modeling augmented by three-dimensional pharmacophore screening. This approach is thought to be particularly relevant for medicinal chemistry applications because it combines knowledge-based elements with deep learning and is chemically intuitive. As an exemplary application, we report for Bruton’s tyrosine kinase (BTK), a major drug target for the treatment of inflammatory diseases and leukemia, the generation of novel candidate inhibitors with a specific chemically reactive group for covalent modification, requiring only little target-specific compound information to guide the design efforts. Newly generated compounds include known inhibitors and characteristic substructures and many novel candidates, thus lending credence to the computational approach, which is readily applicable to other targets.     

Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges

Highlights:

• Multi tyrosine kinase inhibitors licensed for HCC treatment.
• Multi kinase inhibitors not licensed for HCC treatment.
• Inhibitors of Growth Factor Receptors.
• Small molecules acting as immunomodulators.
• Small molecules inhibiting crucial HCC pathways.
• Small molecules targeting various molecular targets.

Simple SummaryLiver cancer is one of the most common types of cancer globally. Its treatment options have been limited. Sorafenib was the most commonly used drug with patients that have advanced liver cancer. Recently, multiple new target proteins and pathways, which play a major role in the disease, have been discovered. Accordingly, researchers have designed and revealed new drugs. Some of them are FDA approved and others are under investigation in clinical trials. The aim of our systematic review is to provide an overview of these recently reported targets and compounds. This review will be useful in identifying unpopular or underrated targets, as well as designing new combination treatment strategies.AbstractAccording to data provided by World Health Organization, hepatocellular carcinoma (HCC) is the sixth most common cause of deaths due to cancer worldwide. Tremendous progress has been achieved over the last 10 years developing novel agents for HCC treatment, including small-molecule kinase inhibitors. Several small molecule inhibitors currently form the core of HCC treatment due to their versatility since they would be more easily absorbed and have higher oral bioavailability, thus easier to formulate and administer to patients. In addition, they can be altered structurally to have greater volumes of distribution, allowing them to block extravascular molecular targets and to accumulate in a high concentration in the tumor microenvironment. Moreover, they can be designed to have shortened half-lives to control for immune-related adverse events. Most importantly, they would spare patients, healthcare institutions, and society as a whole from the burden of high drug costs. The present review provides an overview of the pharmaceutical compounds that are licensed for HCC treatment and other emerging compounds that are still investigated in preclinical and clinical trials. These molecules are targeting different molecular targets and pathways that are proven to be involved in the pathogenesis of the disease.     

Effects of Hydroxyapatite Nanoparticles on Apoptosis and Invasion of Human Renal Cell Carcinoma 786-0 Cells

Renal cell carcinoma is the most common cancer of the kidney, and resistant to traditional therapies. The aim of this study is to investigate the effects of hydroxyapatite nanoparticles on human renal cell carcinoma 786-0 cells. Cell proliferation was assessed with an 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide(MTT) staining kit. The apoptosis assay was assessed with an FITC Annexin V Apoptosis Detection Kit. Caspase-3 and caspase-12 were detected by immunocytochemical staining and semi-qua...     

New application of a subcellular fractionation method to kidney and testis for the determination of conjugated linoleic acid in selected cell organelles of healthy and cancerous human tissues

To clarify the mechanism of the anticarcinogenic effect of conjugated linoleic acid (CLA), its intracellular distribution needs to be determined. Subcellular fractionation using centrifugation techniques is a method that is frequently used for isolation of cell organelles from different tissues. But as the size and density of the organelles differ, the method needs to be optimised for every type of tissue. The novelty of this study is the application of a subcellular fractionation method to human healthy and cancerous renal and testicular tissue. Separation of total tissue homogenate into nuclei, cytosol, and a mixture of mitochondria and plasma membranes was achieved by differential centrifugation. As mitochondria and plasma membranes seemed to be too similar in size and weight to be separated by differential centrifugation, discontinuous density-gradient centrifugation was carried out successfully. The purity of the subcellular fractions was checked by measuring the activity of marker enzymes. All fractions were highly enriched in their corresponding marker enzyme. However, the nuclear fractions of kidney and renal cell carcinoma were slightly contaminated with mitochondria and plasma membrane fractions of all tissues with lysosomes. The fraction designated the cytosolic fraction contained not only cytosol, but also microsomes and lysosomes. The CLA contents of the subcellular fractions were in the range 0.13–0.37% of total fatty acids and were lowest in the plasma membrane fractions of all types of tissue studied. C16:0, C18:0, C18:1 c9, C18:2 n-6, and C20:4 n-6 were found to be the major fatty acids in all the subcellular fractions studied. However, marked variations in fatty acid content between subcellular fractions and between types of tissue were detectable. Because of these differences between tissues, no general statement on characteristic fatty acid profiles of single subcellular fractions is possible.     

Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton’s Tyrosine Kinase via Molecular Dynamics Simulations

Bruton’s tyrosine kinase (BTK) is a key protein from the TEC family and is involved in B-cell lymphoma occurrence and development. Targeting BTK is therefore an effective strategy for B-cell lymphoma treatment. Since previous studies on BTK have been limited to structure-function analyses of static protein structures, the dynamics of conformational change of BTK upon inhibitor binding remain unclear. Here, molecular dynamics simulations were conducted to investigate the molecular mechanisms of association and dissociation of a reversible (ARQ531) and irreversible (ibrutinib) small-molecule inhibitor to/from BTK. The results indicated that the BTK kinase domain was found to be locked in an inactive state through local conformational changes in the DFG motif, and P-, A-, and gatekeeper loops. The binding of the inhibitors drove the outward rotation of the C-helix, resulting in the upfolded state of Trp395 and the formation of the salt bridge of Glu445-Arg544, which maintained the inactive conformation state. Met477 and Glu475 in the hinge region were found to be the key residues for inhibitor binding. These findings can be used to evaluate the inhibitory activity of the pharmacophore and applied to the design of effective BTK inhibitors. In addition, the drug resistance to the irreversible inhibitor Ibrutinib was mainly from the strong interaction of Cys481, which was evidenced by the mutational experiment, and further confirmed by the measurement of rupture force and rupture times from steered molecular dynamics simulation. Our results provide mechanistic insights into resistance against BTK-targeting drugs and the key interaction sites for the development of high-quality BTK inhibitors. The steered dynamics simulation also offers a means to rapidly assess the binding capacity of newly designed inhibitors.     

Synthesis and biological evaluation of a series of novel salicylanilides as inhibitors of EGFR protein tyrosine kinases

The synthesis and biological evaluation of two series of salicylanilide derivatives on the EGFR and ErbB-2 tyrosine kinases inhibitory activities were conducted.Of the tested compounds those having an additional aryl group substituted on the anilino ring were active on the EGFR tyrosine kinase inhibition(7a-c and 13a,13c,13d,13f).The inhibitory activities were all in the low micromolar or submicromolar range.In addition,compound 13a was found to have dual inhibitory activities both on EGFR and ErbB-2 tyrosine kinases(1.654±1.280 and 7.134±1.265μmol/L).